retatrutide joint pain More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase TRIUMPH-4: Retatrutide Delivers Weight Loss,

[3] [14] The FDA has approved several GLP-1 receptor agonists for clinical use, each with distinct characteristics regarding formulation, dosing frequency, and approved indications

You dont have to go hard

Symptoms of hypoglycemia, such as dizziness, confusion, sweating, shakiness, or blurred vision

How the Triple Action Affects Your Body The GLP-1 receptor helps slow down stomach emptying and reduces appetite

Research published in Nutrients (2023) and updated clinical reviews in early 2025 demonstrate that these SCFAs act as chemical keys that unlock the L-cells in your colon, directly triggering the release of GLP-1 into your bloodstream